Eli Lilly’s existing October 2024 research collaboration with Peptron allows evaluation of SmartDepot’s ultrasonic spray-drying platform for sustained-release microsphere formulations of peptide drugs, but stops short of any commercial licensing commitment. Recent reporting highlights Lilly’s strategic pivot toward oral obesity candidates, raising doubts about near-term injectable depot deals. With only weeks remaining until the October 7 resolution date and no announced milestone payments, regulatory filings, or partnership expansions, traders assign an 87.5% probability to “No,” reflecting the gap between early-stage technology assessment and executed license agreements in the competitive peptide-delivery landscape.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui13% peluang
$11,264 Vol.
$11,264 Vol.
Oct 7, 2026
13% peluang
$11,264 Vol.
$11,264 Vol.
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing October 2024 research collaboration with Peptron allows evaluation of SmartDepot’s ultrasonic spray-drying platform for sustained-release microsphere formulations of peptide drugs, but stops short of any commercial licensing commitment. Recent reporting highlights Lilly’s strategic pivot toward oral obesity candidates, raising doubts about near-term injectable depot deals. With only weeks remaining until the October 7 resolution date and no announced milestone payments, regulatory filings, or partnership expansions, traders assign an 87.5% probability to “No,” reflecting the gap between early-stage technology assessment and executed license agreements in the competitive peptide-delivery landscape.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Pasar Dibuka: May 5, 2026, 8:02 PM ET
Volume
$11,264Tanggal Berakhir
Oct 7, 2026Pasar Dibuka
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing October 2024 research collaboration with Peptron allows evaluation of SmartDepot’s ultrasonic spray-drying platform for sustained-release microsphere formulations of peptide drugs, but stops short of any commercial licensing commitment. Recent reporting highlights Lilly’s strategic pivot toward oral obesity candidates, raising doubts about near-term injectable depot deals. With only weeks remaining until the October 7 resolution date and no announced milestone payments, regulatory filings, or partnership expansions, traders assign an 87.5% probability to “No,” reflecting the gap between early-stage technology assessment and executed license agreements in the competitive peptide-delivery landscape.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,264Tanggal Berakhir
Oct 7, 2026Pasar Dibuka
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s existing October 2024 research collaboration with Peptron allows evaluation of SmartDepot’s ultrasonic spray-drying platform for sustained-release microsphere formulations of peptide drugs, but stops short of any commercial licensing commitment. Recent reporting highlights Lilly’s strategic pivot toward oral obesity candidates, raising doubts about near-term injectable depot deals. With only weeks remaining until the October 7 resolution date and no announced milestone payments, regulatory filings, or partnership expansions, traders assign an 87.5% probability to “No,” reflecting the gap between early-stage technology assessment and executed license agreements in the competitive peptide-delivery landscape.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui
Hati-hati dengan link eksternal.
Hati-hati dengan link eksternal.
Pertanyaan yang Sering Diajukan